Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777191 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
NCT01777191 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 204 participants.
The verdict
NCT01777191, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.
Interventions
- DRUG Ixekizumab Auto-Injector
- DRUG Ixekizumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01777191
The ClinicalTrials.gov registry entry for NCT01777191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ixekizumab Auto-Injector is the first listed.
NCT01777191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01777191 about?
NCT01777191 is a clinical study titled "Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.
What is the current status of trial NCT01777191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2013-03. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01777191?
The interventions under investigation include: Ixekizumab Auto-Injector (DRUG), Ixekizumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT01777191?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.